Genmab — Oktober 2018
-
God morgen.
-
-
Godmorgen - ang ASH og yderligere data, så siger GEN selv (jvf hda's link fra Børsen artiklen), at JJ måske vil præsentere flere data. Så måske bliver de sparsomme toplinie data udvidet
-
God morgen
-
-
Er det resultatet af fase 3 forsøget med Daratumumab mod Amyloidosis?
-
God morgen
-
@hda Ok. Jeg læste udelukkende datoen øverst oppe hvor der står 30. oktober 2018. Tak skal du have.
-
Vedr CR-snakken i går aftes. I NEJM-artiklen fra 2014 er CR for Rd continuous på 15% (s. 909 øh). I Final analysis 21%. https://www.nejm.org/doi/pdf/10.1056/NEJMoa1402551 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774211/
-
I Alcyone havde D-VMp 42,6% sCR eller bedre. I Pollux havde D-Rd 42,3% sCR eller bedre. http://www.multiplemyelomahub.com/medical-information/ash-2017-phase-iii-alcyone-clinical-trial-daratumumab-plus-bortezomib-melphalan-and-prednisone-d-vmp-in-ndmm-patients-ineligible-for-transplant https://www.darzalexhcp.com/clinical-studies/pollux-efficacy
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind